Navigation Links
ULURU Inc. Reports Second Quarter 2010 Financial Results
Date:8/17/2010

Mark, the Altrazeal® asset becomes more valuable as the product is now approved for marketing throughout Europe and other markets.  We continue to evaluate potential partnerships and the Chinese agreement is the first of what we believe will be a series of agreements to market Altrazeal® worldwide.  The Chinese agreement, the divestiture of Zindaclin®, and potential additional Altrazeal® agreements will provide the company with additional liquidity in the near term."

Operating ResultsRevenues

Revenue for the second quarter of 2010 was $232,000, compared to $136,000 for the second quarter of 2009.  The increase of $96,000 in revenue was due primarily to an increase of $100,000 in licensing fees related to the achievement of a milestone relating to Zindaclin®.

Research and Development

Research and development expenses for the second quarter of 2010 were $367,000, including $41,000 in share-based compensation, compared to $854,000, including $213,000 in share-based compensation, for the second quarter of 2009.  The decrease of $487,000 in research and development expenses continues to reflect the impact of the Company's restructured business plan which contributed to decreases in scientific personnel costs of $356,000, regulatory consulting expenses of $128,000, and clinical testing expenses for our wound care technologies of $66,000.  These expense decreases were partially offset by an increase in regulatory fees of $37,000 and direct research costs of $33,000.

Selling, General and Administrative

Selling, general and administrative expenses for the second quarter of 2010 were $0.9 million, including $47,000 in share-based compensation, compared to $1.8 million, including $279,000 in share-based compensation, for the second quarter of 2009.  The decrease of $913,000 in selling, general and administrative expenses continues to reflect the impact of
'/>"/>

SOURCE ULURU Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
2. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2009 and to Provide a Business Update
4. ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference
5. ULURU Inc. Obtains Status of Approved Supplier With McKesson.
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. Spherix Reports Second Quarter Earnings
8. Tapestry Reports Second Quarter 2007 Results
9. Callisto Reports on Second-Quarter 2007 Milestones
10. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
11. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)...  Adeptus Health Inc. (NYSE: ADPT ) (the ... the previously announced offering of 2,100,000 shares of its ... to be sold by the Company, and 750,329 shares ... Partners (the "Selling Stockholder"), at a price to the ... and the Selling Stockholder have granted the underwriters an ...
(Date:5/5/2015)... BOSTON , May 5, 2015   InspireMD, Inc. ... in embolic protection systems, announced today that it will release ... 31, 2015 on Monday, May 11 th before the ... to review its financial results and business outlook. ... ) or (412) 542-4135 (International) and request the InspireMD call. ...
(Date:5/5/2015)... Calif. , May 5, 2015 ... biopharmaceutical company focused on cardio-renal, gastrointestinal, and metabolic ... clinical trial evaluating tenapanor in Stage 3 chronic ... and albuminuria did not meet the primary endpoint ... patients compared to patients receiving placebo. ...
Breaking Medicine Technology:Adeptus Health Inc. Announces Pricing of Common Stock Offering 2Adeptus Health Inc. Announces Pricing of Common Stock Offering 3Adeptus Health Inc. Announces Pricing of Common Stock Offering 4InspireMD to Report Financial Results for the First Quarter Ended March 31, 2015 on Monday, May 11th 2InspireMD to Report Financial Results for the First Quarter Ended March 31, 2015 on Monday, May 11th 3Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 2Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 3Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 4Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 5Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 6
(Date:5/5/2015)... (PRWEB) May 05, 2015 With the FCPX ... can quickly and easily add washed color grades to footage. ... formula for modifying an image. The LUT changes every pixel's ... pack comes with 90 washed CUBE LUT files. , This ... Monochromatic can give any footage a washed look. , ...
(Date:5/5/2015)... 2015 Private equity consultant and international ... announced that its dental stem cell biobank project, ... again--in April, 2015 –and posted yet another exciting record. ... volume and represents a significant 54% increase over last ... biobank is conducted via the Store-A-Tooth brand. The company ...
(Date:5/5/2015)... Beverly Hills Cosmetic Dentist, Arthur Glosman released a luxury ... sold at the offices of Arthur Glosman DDS, 450 N ... an online store . “I wanted to be one ... care and beauty with a luxurious collection of products designed ... , Dr. Glosman’s Advanced Dental Health + Beauty™ products ...
(Date:5/5/2015)... NCPDP announced today that AmerisourceBergen ... a three-year commitment of strategic support for NCPDP, and ... “AmerisourceBergen has supported our multi-stakeholder forum over 3 decades,” ... is a wonderful continuation and expansion of its commitment ... back to our very first Board of Trustees in ...
(Date:5/5/2015)... AxoGen, Inc. (NASDAQ: AXGN), ... billion peripheral nerve repair market, reported record revenue of ... 2015 compared to $3.14 million in the year-ago first ... proprietary portfolio of nerve repair products - Avance® ... – and our solid sales execution delivered another record ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Announced the Release of FCPX LUT Monochromatic 2Health News:Grace Century’s Dental Stem Cell Biobank Project Announces Serial Record Enrollment Growth 2Health News:Grace Century’s Dental Stem Cell Biobank Project Announces Serial Record Enrollment Growth 3Health News:Beverly Hills Dentist Arthur Glosman Launches New Dental Health And Beauty Product Line 2Health News:AmerisourceBergen Joins NCPDP Elite Partner Program 2Health News:AmerisourceBergen Joins NCPDP Elite Partner Program 3Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 2Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 3Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 4
... to Nutrition experts, some new ways of getting the ... that omega-6 fatty acids are associated with chronic diseases, ... regular daily diet naturally// includes some of each. ... your omega-3s from fish like sardines, salmon and tuna. ...
... spend more for health care and medications than smokers, ... health hazards. While tobacco is still the nation's principal ... obesity was running a close second. ,For ... Corp. economist Roland Sturm used data from two national ...
... human diet mean people today are more at risk of ... the University of Newcastle believe that changes to the way ... anti-cancer agents. ,The researchers are working on a ... stomach cancer. They are carrying out two trials on people ...
... in hospital who smoke and have a history of ... surveyed almost 400 patients// to find if there was ... classified them into four groups:current tobacco use only, history ... ,The patients with both current tobacco use and past ...
... According to researchers reducing weight and increasing exercise cut ... have elevated blood sugar are known to be at ... serious even life-threatening complications, it would be very useful ... individuals avoid the disease. ,Researchers for the ...
... longtime sufferers. New research shows that a combination of ... the severity and frequency of chronic tension headches, which ... people with mild to moderate head pain that occurs ... six months. Although antidepressants require a prescription, they may ...
Cached Medicine News:
... been selling replacement bulbs on ... we are extremely proud of ... out our catalog of replacement ... light bulbs specials. ,Check ...
... Bulb Direct has been selling ... since 1996, and we are ... satisfaction guarantee. Check out our ... see our discount light bulbs ...
... has been selling replacement bulbs ... and we are extremely proud ... Check out our catalog of ... discount light bulbs specials. ...
... Symphony family of Pacemakers, Ela presents the ... lighter than a passport, will take your ... technologies, and delivering powerful monitoring. ELA ... dual-chamber and atrial tracking modes in patients ...
Medicine Products: